US Activist Hedge Fund Institutional SEC 13D 13G — August 18, 2026

18-08-2026

Patriot Financial Partners II, L.P. and related entities filed an amended Schedule 13G/A with the SEC on August 18, 2026, disclosing their aggregate beneficial ownership of CoastalSouth Bancshares, Inc. (COSO) common stock. The filing reveals that the Patriot group collectively holds approximately 1,130,164 shares (about 9.5% of the outstanding voting common stock) as of August 14, 2026. Notably, the group sold a total of 118,385 shares over three days in mid-August 2026 at prices between $27.81 and $27.88 per share, indicating a partial reduction in their position.

• · The filing is an amendment to a Schedule 13G originally filed on September 17, 2025.
• · The group's aggregate beneficial ownership is approximately 9.5% of the outstanding shares, calculated by summing the individual holdings (506,038 + 565,082 + 59,044 = 1,130,164 shares).
• · The sales occurred on three consecutive trading days: August 12 (74,871 + 8,736 = 83,607 shares), August 13 (14,680 + 1,713 = 16,393 shares), and August 14 (16,464 + 1,921 = 18,385 shares).
• · The filing is made pursuant to Rule 13d-1(d) under the Securities Exchange Act of 1934.

18-08-2026

CB Beteiligungs GmbH & Co. KG and affiliated entities disclosed in a Schedule 13D/A that their beneficial ownership in Birkenstock Holding plc remained unchanged at 16,763,510 ordinary shares (10.2% of outstanding shares) following the company's August 2026 redemption and cancellation of 12,761,613 shares. The reporting persons did not acquire or dispose of any shares in connection with the secondary offering or the share repurchase. CEO Oliver Reichert separately holds 1,361,273 shares and has a contractual subparticipation in CBB's stake, but disclaims beneficial ownership of CBB's shares except for his pecuniary interest.

• · The filing is an amendment to Schedule 13D originally filed on January 26, 2026, and amended on February 27, 2026.
• · CB Birkenstock Stiftung has sole voting and dispositive power over the 16,763,510 shares held by CBB.
• · CEO Oliver Reichert has a contractual right to 10% of the economic interest (subparticipation) in CBB's shares, but disclaims beneficial ownership except for pecuniary interest.
• · No transactions in Birkenstock ordinary shares were effected by the reporting persons in the 60 days prior to the filing.
• · The reporting persons have not been involved in any criminal or civil securities-related proceedings in the last five years.

18-08-2026

OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC filed a Schedule 13D disclosing beneficial ownership of 2,714,279 shares of BlossomHill Therapeutics, Inc. (BLSM), representing 8.9% of outstanding common stock. The shares are held through OrbiMed Private Investments VIII, LP (OPI VIII), which acquired them via Series A and Series B preferred stock conversions and IPO purchases. The filing indicates an investment purpose without plans to acquire control, but notes that Carl L. Gordon, a member of OrbiMed Advisors, serves on BlossomHill's board, giving OrbiMed potential influence.

• · The shares were acquired through conversion of Series A preferred stock (1,039,996 shares purchased March 2021) and Series B preferred stock (1,049,283 shares purchased December 2023) at a 1-for-1 ratio upon IPO completion, plus 625,000 shares purchased in the IPO at $16.00 per share.
• · OrbiMed Advisors and OrbiMed GP share voting and dispositive power over the 2,714,279 shares held by OPI VIII.
• · Carl L. Gordon serves on BlossomHill's board and is obligated to transfer any equity compensation received to OrbiMed Advisors for the benefit of OPI VIII.
• · OPI VIII and Gordon are subject to a 180-day lock-up agreement from the date of the final prospectus supplement relating to the IPO.
• · Holders of at least 70% of registrable securities may demand Form S-1 registration starting 180 days after the IPO effective date; holders of at least 30% may request Form S-3 registration if anticipated net proceeds are at least $1 million.
• · Registration rights expire on the earliest of: a deemed liquidation event, when shares can be sold under Rule 144 without restriction within three months, or the third anniversary of the IPO.

18-08-2026

BasePoint Group Inc. has filed a Schedule 13D disclosing beneficial ownership of 23,414,790 shares of Katapult Holdings, Inc. common stock, representing 26.8% of the approximately 87,400,000 shares outstanding. The shares were acquired in connection with Katapult's merger completed on August 11, 2026, with the bulk (22,801,805 shares) issued as non-cash merger consideration for pre-merger holdings in certain entities, and an additional 612,985 shares received as partial satisfaction of contingent payment obligations. BasePoint Group, an asset-based financing firm, states it holds the securities for investment purposes and may acquire additional shares or sell its stake depending on market conditions.

• · The shares are held by BP Launch Aggregator LLC, an indirect wholly-owned subsidiary of BasePoint Group Inc.
• · BasePoint Group has not effected any transactions in Katapult common stock within the last 60 days prior to the filing.
• · BasePoint Group's principal business is providing asset-based financing to commercial, fintech and consumer originators.

18-08-2026

OrbiMed Advisors LLC and affiliated entities filed a Schedule 13D disclosing beneficial ownership of 12,175,159 shares (17.2%) of Braveheart Bio, Inc. as of August 7, 2026. The stake is held through OrbiMed Private Investments IX, LP (11,901,826 shares, 16.9%) and OrbiMed Genesis Master Fund, L.P. (273,333 shares, 0.4%). The filing indicates the investment was made for investment purposes and not to acquire control, with no current plans for extraordinary corporate transactions.

• · The Series A preferred stock converted into common shares at a ratio of 1-for-4.38 upon completion of the IPO.
• · OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu.
• · Erez Chimovits, an employee of OrbiMed Advisors, serves on the Board of Directors of Braveheart Bio and is obligated to transfer any equity compensation to OrbiMed Advisors for OPI IX.
• · The Investors' Rights Agreement grants demand registration rights (Form S-1) beginning 180 days after the IPO effective date and piggyback registration rights, as well as Form S-3 registration rights.
• · No transactions in Shares were effected by the Reporting Persons during the past 60 days except as disclosed in Item 3.

18-08-2026

Soleus Capital Master Fund, L.P. and related entities disclosed a 5.8% beneficial ownership stake in Processa Pharmaceuticals, Inc. as of August 3, 2026, holding 160,943 shares of common stock. The filing is a routine Schedule 13G by a passive investor, indicating no intent to change or influence control of the company.

• · The filing was made pursuant to Rule 13d-1(c), indicating a passive investment.
• · Soleus Capital Master Fund, L.P. is organized in the Cayman Islands; the other reporting entities are Delaware entities.
• · Guy Levy is the ultimate controlling person of the reporting entities.

18-08-2026

Brown Brothers Harriman & Co. and its affiliate Brown Brothers Harriman Credit Partners, LLC filed an amended Schedule 13D disclosing an increased beneficial ownership of 51.69% in AMG BBH Asset-Backed Credit Fund, LLC (formerly AMG BBH Asset-Backed Fund, LLC). The filing reports recent purchases of 107,542.96 Class S Units at approximately $11.15-$11.16 per share on August 14 and 17, 2026, using working capital and client account funds. The filing is a routine ownership update with no negative or flat performance metrics to report.

• · The issuer changed its name from AMG BBH Asset-Backed Fund, LLC to AMG BBH Asset-Backed Credit Fund, LLC effective November 19, 2025.
• · The filing is an amendment to the original Schedule 13D filed on July 14, 2026.
• · No transactions in the issuer's securities were reported during the 60 days prior to this filing other than those listed in Exhibit 99.2.

18-08-2026

Maximilian Martin filed an amended Schedule 13D disclosing ownership of 12,722,637 shares of Enhanced Group Inc. (formerly AParadise Acquisition Corp.) Class A Common Stock, representing a 9.6% stake as of August 14, 2026. The filing details a private placement on June 14, 2026, where Martin acquired 1,285,347 shares and accompanying warrants at a combined price of $3.89 per unit, for an aggregate purchase price of approximately $5 million. The filing shows a significant increase in Martin's holdings, but no negative or flat metrics are present.

• · Martin's total beneficial ownership includes 11,437,290 shares held directly and 1,285,347 shares underlying warrants.
• · The private placement closed on August 14, 2026, after stockholder consent became effective.
• · A registration rights agreement requires the issuer to file a resale registration statement within 30 days of closing and use best efforts to have it declared effective within 90 days of filing (or 5 business days after SEC notice of no review).
• · The issuer's principal executive offices are at 169 Madison Avenue, Suite 15101, New York, NY 10016.

18-08-2026

Voss Capital, LP and related entities filed a Schedule 13G with the SEC on August 18, 2026, disclosing beneficial ownership of 12,700,000 ordinary shares of Cellebrite DI Ltd., representing approximately 5.1% of the outstanding shares. The filing indicates that Voss Capital and its managing member Travis W. Cocke each hold a 5.1% stake, while the Voss Value Master Fund and Voss Value-Oriented Special Situations Fund own smaller positions of 0.7% and 0.1%, respectively. The filing is a passive investment disclosure under Rule 13d-1(c), with no intent to change or influence control of the issuer.

• · The filing is made under Rule 13d-1(c), indicating passive investment intent with no control purpose.
• · Voss Capital, LP directly holds 10,400,000 shares and has shared dispositive power over 2,300,000 shares.
• · Travis W. Cocke directly holds 10,400,000 shares and has shared dispositive power over 2,300,000 shares.
• · The aggregate beneficial ownership percentage is based on 250,785,933 shares outstanding as of June 30, 2026.
• · A Joint Filing Agreement (Exhibit 99.1) was executed by all reporting persons.

18-08-2026

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, filed a Schedule 13G disclosing beneficial ownership of 286,866 ordinary shares of Silexion Therapeutics Corp, representing 4.99% of the outstanding shares as of August 18, 2026. This filing follows a Securities Purchase Agreement (SPA) on August 11, 2026, under which the group initially held 149,724 shares (9.99% of a smaller share base), but subsequent share issuance and warrant exercises reduced their stake to below 5%. The filing includes blocker provisions that prevent the exercise of certain warrants beyond specified ownership thresholds, capping potential ownership at 4.99% or 9.99% depending on the warrant.

• · The filing is made under Rule 13d-1(c), indicating the shares were not acquired to change or influence control of the issuer.
• · Intracoastal Capital LLC is a Delaware limited liability company with principal office at 245 Palm Trail, Delray Beach, FL 33483.
• · Mitchell P. Kopin and Daniel B. Asher are U.S. citizens and serve as managers or members of Intracoastal.
• · The SPA was executed on August 11, 2026, and disclosed in a Form 8-K filed on August 13, 2026.
• · Multiple warrants (Intracoastal Warrant 1, 2, 3, 4) contain blocker provisions limiting exercise to 4.99% or 9.99% beneficial ownership.
• · The reporting persons disclaim beneficial ownership of shares held by others, except to the extent of their pecuniary interest.

18-08-2026

Saba Capital Management, L.P. and related parties filed Amendment No. 9 to their Schedule 13D, disclosing a 5.63% beneficial ownership stake in NYLI CBRE Global Infrastructure Megatrends Term Fund (MEGI), representing 2,928,750 common shares. The filing details a series of open-market sales by Saba Capital from June 26 to August 17, 2026, totaling approximately 538,000 shares sold at prices ranging from $15.05 to $15.57. The total cost to acquire the reported shares was approximately $38.56 million.

• · Saba Capital sold approximately 538,000 shares during the period, with the largest single-day sale of 45,415 shares on August 3, 2026 at $15.20.
• · The filing is an amendment (No. 9) to the initial Schedule 13D filed on June 29, 2026.
• · Shares were acquired using subscription proceeds, capital appreciation, and margin account borrowings; margin positions are pledged as collateral.
• · The fund was formerly named MainStay CBRE Global Infrastructure Megatrends Term Fund (name changed June 30, 2023).

18-08-2026

Baihui Partners L.P. filed an amended Schedule 13D (Amendment No. 3) with the SEC on August 18, 2026, disclosing beneficial ownership of 849,601,280 Class A ordinary shares of KE Holdings Inc. (BEKE), representing 24.7% of total outstanding ordinary shares. The filing was triggered by a change in ownership percentage due to the company's share repurchase and cancellation, which reduced the total share count, rather than any new transactions by the reporting person. Baihui Partners L.P. has not effected any transactions in the Class A ordinary shares during the past 60 days.

• · The filing is Amendment No. 3 to the original Schedule 13D filed on July 29, 2021.
• · The change in beneficial ownership percentage (to 24.7%) is solely due to the issuer's share repurchase and cancellation, not any transactions by the reporting person.
• · Baihui Partners L.P. holds voting power over the shares via an Irrevocable Proxy and Power of Attorney from Propitious Global Holdings Limited.
• · No transactions in Class A ordinary shares were effected by the reporting person in the past 60 days.

18-08-2026

Jeffrey Sharpe, a director of Conexeu Sciences Inc., filed a Schedule 13D disclosing beneficial ownership of 1,500,000 shares (5.4% of outstanding common stock) as of August 17, 2026. This includes 1,000,000 shares held directly and 500,000 shares issuable upon exercise of vested performance warrants (June 2026 Vested Warrants). The filing updates his ownership after the vesting of warrants tied to the company's achievement of an $80 million market capitalization milestone, while 500,000 additional warrants remain unvested pending a 510(k) submission to the FDA.

• · Sharpe exercised 500,000 warrants on May 22, 2026 (vested May 21, 2026 upon Nasdaq listing) at $0.001/share, paying $500 total.
• · Sharpe previously exercised 500,000 warrants on December 23, 2025 (vested July 8, 2025 upon collagen study completion) at $0.001/share, paying $500 total.
• · The unvested 500,000 warrants (Milestone 4) will only vest upon submission of a 510(k) application to the FDA.
• · Sharpe has sole voting and dispositive power over all 1,000,000 directly held shares and sole power to acquire the 500,000 warrant shares.
• · No transactions in common stock occurred in the 60 days prior to filing other than the May 22, 2026 exercise.
• · Sharpe may acquire or dispose of securities in open market or private transactions depending on market conditions.

18-08-2026

A Schedule 13G filing reveals that AI Biotechnology LLC, an entity controlled by Len Blavatnik via Access Industries, holds 3,185,177 shares of Latigo Biotherapeutics, Inc., representing 5.0% of the outstanding common stock as of August 11, 2026. The percentage is based on 63,238,030 shares outstanding immediately after the company's IPO, as reported in its August 7, 2026 prospectus. The filing is a passive investment disclosure under Rule 13d-1(c) and does not indicate any intent to change control of the issuer.

• · The shares are held directly by AI Biotechnology LLC.
• · Beneficial ownership is also reported by Access Industries Holdings LLC, Access Industries Management, LLC, and Len Blavatnik due to control relationships.
• · The filing is made pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934.
• · Each reporting person disclaims beneficial ownership of the securities except AI Biotechnology LLC.
• · The filing certifies that the securities were not acquired with the purpose of changing or influencing control of the issuer.

18-08-2026

TPG GP A, LLC, along with James G. Coulter and Jon Winkelried, filed Amendment No. 9 to their Schedule 13D, disclosing beneficial ownership of TPG Inc. Class A Common Stock. The filing reports that on August 14, 2026, 6,960,798 Common Units were exchanged for an equal number of Class A shares, increasing the total outstanding Class A shares to 377,918,766 (including shares issuable upon exchange of remaining Common Units). TPG GP A is deemed to beneficially own 55.8% of the Class A shares, while Mr. Coulter and Mr. Winkelried own 56.4% and 56.0%, respectively, reflecting their continued majority control.

• · The Q3 2026 Exchange occurred on August 14, 2026, involving 6,960,798 Common Units exchanged for Class A shares.
• · TPG GP A is the managing member of two LLCs that serve as general partners of entities holding Class B Common Stock and Common Units.
• · Peppertree Holders directly hold an aggregate of 5,372,330 Common Units and an equal number of Class B shares, and TPG GP A may be deemed beneficial owner of those securities.
• · The filing amends Items 2(a), 4, and 5 of the original Schedule 13D, reflecting the Q3 2026 Exchange and updated ownership percentages.

18-08-2026

Bob Gene Gower, Chairman of Ensysce Biosciences, filed an amended Schedule 13D disclosing an increased beneficial ownership of 6.1% of the company's common stock. The boost comes from a $198,000 open-market purchase of 400,000 shares on August 7, 2026, and a prior conversion of convertible notes into 508,614 shares and a warrant. Mr. Gower has entered into a Support Agreement tied to a planned merger with Cy Biopharma, Inc., obligating him to vote his shares in favor of proposals to approve a reverse stock split and other charter amendments.

• · Bob Gower held less than 5% before the August 7, 2026 purchase and the April 23 conversion.
• · The Support Agreement requires Gower to vote in favor of proposals including a reverse stock split to maintain Nasdaq listing standards.
• · Gower may also be entitled to future equity compensation under the company's 2021 Omnibus Incentive Plan.
• · The merger with Cy Biopharma was announced on August 5, 2026, as per a Form 8-K.

18-08-2026

Taiji Ito filed a Schedule 13G with the SEC on August 18, 2026, disclosing beneficial ownership of 39,613,355 shares of Advasa Holdings, Inc. common stock, representing an 8.13% stake. The filing is made under Rule 13d-1(c) and certifies that the securities were not acquired with the purpose of changing or influencing control of the issuer.

• · The filing is a Schedule 13G (passive investment) under Rule 13d-1(c), indicating Ito does not intend to influence control.
• · Ito's address is listed as c/o Advasa Holdings, Inc. in Tokyo, Japan.
• · The issuer's total outstanding shares are 487,065,702, based on its Form 10-Q filed August 12, 2026.

18-08-2026

Marc Cywinski and his entity Solerin Equity Limited have filed a Schedule 13D/A disclosing beneficial ownership of 5,360,000 Class A Ordinary Shares and 7,500,000 Class B Ordinary Shares of SunScout Holding Ltd, representing 23.20% of the voting power of the Class A shares and 50% of the voting power of the Class B shares. The filing indicates sole voting and dispositive power over all reported shares, with no shared power. This represents a significant concentrated ownership position, particularly in the Class B shares which carry 20 votes per share.

• · Each Class A Ordinary Share carries one vote; each Class B Ordinary Share carries twenty votes.
• · Marc Cywinski is the Chief Operations Officer of SunScout Holding Ltd.
• · The filing is an amendment (Schedule 13D/A) dated August 18, 2026, with the transaction date of August 11, 2026.

18-08-2026

Prescott General Partners LLC and related entities filed Amendment No. 13 to Schedule 13D, disclosing aggregate beneficial ownership of 1,446,175 shares (31.0% of outstanding) in World Acceptance Corp as of August 14, 2026. On that date, the group sold 133,199 shares to the company at $187.69 per share under its share repurchase program, reducing their collective stake from prior levels. The filing notes no present plans for major corporate actions, though the group may engage with management to maximize shareholder value.

• · Scott J. Vassalluzzo serves as a director of World Acceptance Corp and beneficially owns 30,000 shares for his own account.
• · Thomas W. Smith may be deemed to beneficially own 483,000 shares held by Ridgeview Smith Investments LLC.
• · The group disclaims any present plan or proposal for major corporate actions enumerated in Item 4 of Schedule 13D.
• · No other reporting persons effected any transactions since the prior filing on July 7, 2026.

18-08-2026

An amended Schedule 13D filed on August 18, 2026 discloses that Eclipse Ventures-related entities, together with director Lior Susan, beneficially own an aggregate of 9,555,990 shares of Cerebras Systems Inc. Class A common stock, representing approximately 4.3% of the total common shares outstanding (on a combined Class A and Class B basis). The filing details holdings across multiple Eclipse funds and Mr. Susan's personal and controlled accounts, with all shares being Class A stock; a notable structural feature is that Class B shares carry 20 votes per share versus 1 vote each for Class A.

• · Lior Susan directly holds 197,784 shares personally and another 160,791 shares through an estate-planning vehicle.
• · Class B shares (111,601,424 outstanding) have 20 votes per share, while Class A shares (112,247,109 outstanding) have 1 vote per share, creating a significant voting power disparity.
• · The Eclipse fund holdings are broken down as: Eclipse I (3,768,448 shares), Eclipse Continuity I (546,645 shares), Eclipse SPV II (4,472,603 shares), and Eclipse SPV XIII (409,719 shares).
• · Eclipse Continuity GP I, LLC holds 546,645 shares (0.2% of total common) as the general partner for Eclipse Continuity I.
• · The filing is Amendment No. 2 to the original Schedule 13D filed May 22, 2026, and amended on June 26, 2026.

18-08-2026

PSB Financial, Inc. Employee Stock Ownership Plan Trust filed a Schedule 13G disclosing beneficial ownership of 137,540 shares of PSB Financial, Inc. common stock, representing an 8.0% stake as of June 30, 2026. The trust holds these shares in the ordinary course of business without any intent to change or influence control of the issuer.

• · The filing was made pursuant to Rule 13d-1(b) under the Securities Exchange Act of 1934.
• · The trust had sole voting power over 137,540 shares and sole dispositive power over 137,540 shares.
• · The issuer's common stock has a par value of $0.01 per share.
• · The reporting person is organized under the laws of Montana.

18-08-2026

NovastraList Horizon Ltd., wholly owned by Chang Gil LEE, disclosed a 10.46% beneficial ownership stake in Jin Medical International Ltd. (ZJYL) via a Schedule 13G filing on August 18, 2026. The filing indicates the shares were not acquired with the purpose of changing or influencing control of the issuer.

• · The filing was made under Rule 13d-1(c), indicating a passive investment intent.
• · NovastraList Horizon Ltd. is incorporated in the British Virgin Islands; Chang Gil LEE is a South Korean resident.
• · Chang Gil LEE disclaims beneficial ownership beyond his pecuniary interest in the shares held by NovastraList Horizon Ltd.

18-08-2026

Catalyst4, Inc. and its affiliated reporting persons (Robert Brown, Ekemini Riley, Mark Vorsatz) have filed an amended Schedule 13D disclosing that as of August 14, 2026, they beneficially own 27,536,011 shares of MapLight Therapeutics, representing 49.9% of outstanding voting common stock. This ownership follows a PIPE offering completed August 14, 2026, in which Catalyst4 purchased 4,400,000 shares at $11.38 per share and pre-funded warrants for up to 2,928,686 additional shares, for total consideration of $83.4 million. The ownership percentage is calculated based on 55,077,530 shares outstanding (including 52,848,208 shares outstanding plus 2,229,322 shares issuable upon warrant exercise within 60 days), and the reporting persons are contractually capped at 49.99% beneficial ownership, with 699,364 pre-funded warrants currently unexercisable due to this limit.

• · The PIPE Offering closed on August 14, 2026.
• · The securities purchase agreement for the PIPE was entered into on August 13, 2026.
• · The pre-funded warrants are exercisable at any time and do not expire until exercised in full, but are subject to a 49.99% beneficial ownership blocker.
• · The purchase price for pre-funded warrants is the Purchase Price ($11.38) minus $0.0001 per underlying share.
• · No other transactions in the issuer's common stock were effected by the reporting persons during the 60 days prior to the filing, except those described in Items 4 and 6 of the Schedule 13D.
• · A Registration Rights Agreement was entered into in connection with the PIPE Offering.

18-08-2026

Alco Investment Company filed an amended Schedule 13D with the SEC on August 18, 2026, reporting that its beneficial ownership in Banzai International, Inc. has fallen below 5% to approximately 0.4% as of August 17, 2026. The decline is solely due to dilutive equity issuances by Banzai in 2025, and Alco has not engaged in any transactions in the company's securities since its prior filing on April 23, 2025.

• · Alco's beneficial ownership dropped from above 5% to 0.4% due to dilutive equity issuances by Banzai in 2025.
• · Alco has not conducted any transactions in Banzai securities since April 23, 2025.
• · The 13,556 shares include 6,899 shares held directly and 6,657 shares issuable upon exercise of Common Warrants issued on September 20, 2024, adjusted for reverse stock splits on May 8, 2026 and July 8, 2025.

18-08-2026

Millennium Management LLC, together with Millennium Group Management LLC and Israel A. Englander, filed a Schedule 13G on August 18, 2026, disclosing beneficial ownership of 2,156,891 shares of Tenax Therapeutics, Inc. common stock, representing a 5.8% stake. The filing is made under Rule 13d-1(c) and certifies that the securities were not acquired with the purpose of changing or influencing control of the issuer.

• · The filing is a Schedule 13G (passive investment), not a 13D (activist filing).
• · The reporting persons disclaim beneficial ownership of the securities held by underlying entities.
• · The filing was made pursuant to Rule 13d-1(c), indicating the securities were not acquired to influence control.
• · A Joint Filing Agreement was executed on August 17, 2026, among the three reporting persons.

18-08-2026

Ian Jacobs filed a Schedule 13G/A disclosing beneficial ownership of 475,000 shares of Matternet, Inc. (formerly Los Altos Ventures Corp.) common stock, representing 0.98% of shares outstanding as of June 30, 2026. The stake includes 325,000 common shares, 75,000 shares issuable upon conversion of a secured promissory note, and 75,000 shares underlying warrants from a May 2026 merger. The filing reflects a passive investment (Rule 13d-1(d)) with no material change in ownership from the prior filing.

• · The filing is an amendment (Schedule 13G/A) filed on August 18, 2026.
• · The issuer changed its name from Los Altos Ventures Corp. to Matternet, Inc. on June 27, 2026.
• · The 75,000 warrant shares were issued upon consummation of a merger on May 22, 2026.
• · Ian Jacobs is a U.S. citizen with address in Boca Raton, Florida.
• · The filing indicates sole voting and dispositive power over all 475,000 shares.

18-08-2026

The filing is a Schedule 13G submission by an institutional investor, indicating a passive stake in Skye Bioscience, Inc. as of August 18, 2026. The filing discloses beneficial ownership of shares, but no activist intent, board representation demands, or strategic changes are stated. Ownership percentage and specific financial metrics are NOT_DISCLOSED in the filing summary provided.

• · The filing type is Schedule 13G, indicating passive investment intent (not activist).
• · No stated purpose of the investment beyond passive ownership.
• · No transactions, prices, or timeliness details are available from the filing summary.
• · No history of activism by this specific investor is referenced in the filing.

18-08-2026

Digital Currency Group (DCG) and its wholly-owned subsidiary Fortitude Mining Holdings filed a Schedule 13D disclosing a 9.4% stake (411,522 shares) in HeartSciences Inc., acquired for $999,998.46 via a subscription agreement on August 12, 2026. The filing also details a pending merger agreement (June 23, 2026, amended July 27, 2026) under which Fortitude will contribute its mining platform and $2M cash to HeartSciences, resulting in Fortitude holding ~95% voting power of the combined company (to be renamed Fortitude Mining Group, Inc.). Notably, DCG consented to a SEC cease-and-desist order in January 2025 and paid a $38M penalty for misleading investors regarding Genesis Global's financial condition.

• · Fortitude is currently wholly owned by DCG.
• · The Subscription Agreement includes a registration right for the 411,522 shares only if the Merger Agreement is terminated and the Transactions are not consummated.
• · The Merger Agreement provides an Exchange Ratio of 19.00 (or 21.22 if HeartSciences' VWAP equals or exceeds $7.50 per share).
• · Post-merger, the combined company will be renamed 'Fortitude Mining Group, Inc.' and will be a 'controlled company' under Nasdaq rules.
• · The board of directors and executive officers of HeartSciences will be replaced by Fortitude designees upon closing.
• · DCG consented to a SEC cease-and-desist order in January 2025 and paid a $38M penalty for misleading investors regarding Genesis Global's financial condition.

18-08-2026

Fresenius Medical Care Holdings, Inc. (FMCH) and its parent Fresenius Medical Care AG (FME AG) filed Amendment No. 11 to their Schedule 13D, reporting that as of August 17, 2026, their beneficial ownership in Humacyte, Inc. common stock fell below 5% to approximately 4.9% (13,603,235 shares). The filing also discloses a series of sales executed under a Rule 10b5-1 plan from August 10-17, 2026, totaling approximately 4,709,500 shares at declining weighted-average prices ranging from $0.7249 to $0.5547 per share, generating aggregate proceeds of about $2.78 million. Additionally, the filing notes a change in FME AG's management board, with Ms. Cassie McLean succeeding Mr. Craig Cordola as CEO of the Care Delivery segment and President/CEO of FMCH effective August 1, 2026.

• · The sales were executed under a Rule 10b5-1 Plan established on July 10, 2026 with Citigroup Global Markets Inc. as agent.
• · The weighted-average sale price declined from $0.7249 on August 10 to $0.5547 on August 17, a drop of approximately 23.5% over the six trading days.
• · FMCH ceased to be a beneficial owner of more than 5% of Humacyte's common stock on August 17, 2026.
• · The 13,603,235 shares reported exclude any contingent shares that may be issued under the Business Combination Agreement.
• · Ms. Cassie McLean assumed her roles effective August 1, 2026, succeeding Mr. Craig Cordola who retired on July 31, 2026.

18-08-2026

Yinan Ren filed Amendment No. 1 to Schedule 13D with the SEC on August 18, 2026, solely to correct the percentage of Class A ordinary shares beneficially owned in YY Group Holding Ltd. The original filing incorrectly stated 12,836,734 shares outstanding; the correct figure is 7,836,734 shares. As a result, Ren's beneficial ownership percentage is corrected to 48.33% (from the previously reported lower percentage), while the number of shares owned remains unchanged at 3,787,379.

• · The amendment corrects an error in the original Schedule 13D filed on August 12, 2026.
• · The original filing used an incorrect outstanding share count of 12,836,734 provided by the transfer agent.
• · The corrected outstanding share count is 7,836,734 as of August 14, 2026.
• · Ren's 3,787,379 shares were issued on August 3, 2026, under a Sale and Purchase Agreement with the issuer, in satisfaction of SGD 3,600,000 of purchase consideration.
• · Ren has sole voting and dispositive power over all 3,787,379 shares; no shared power.
• · No other transactions in Class A ordinary shares were effected by Ren in the past 60 days.

18-08-2026

Seah Chia Yee filed a Schedule 13G with the SEC on August 18, 2026, reporting beneficial ownership of 146,539 shares of Addentax Group Corp. (ATXG) common stock, representing a 10.3% stake in the company based on 1,427,974 shares outstanding. The filing indicates a passive investment intent under Rule 13d-1(c), with no plans to change or influence control of the issuer.

• · The filing is a Schedule 13G, indicating the investor qualifies as a passive investor under Rule 13d-1(c) and has no intent to influence control of Addentax.
• · Seah Chia Yee's address is in Shah Alam, Malaysia, and the subject company's business address is in Shenzhen City, China.
• · The beneficial ownership includes sole voting and sole dispositive power over all 146,539 shares; no shared power is reported.

18-08-2026

Clearthink Capital Partners, LLC filed a Schedule 13G with the SEC on August 18, 2026, disclosing beneficial ownership of 9.90% of Edgemode, Inc. common stock as of August 17, 2026. The filing indicates the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

• · The filing is made under Rule 13d-1(b), indicating the filer is a passive investor.
• · Clearthink Capital Partners is a Delaware limited liability company with a business address in New York, NY.
• · The filing certifies the securities were not acquired to change or influence control of the issuer.

18-08-2026

Clear Street Derivatives LLC filed a Schedule 13G/A with the SEC on August 18, 2026, disclosing beneficial ownership of 3,550,631 shares of Kartoon Studios, Inc. (TOON) common stock as of June 30, 2026. This represents a 5.71% ownership stake in the company, making Clear Street a significant shareholder. The filing indicates no dispositive or voting power over the shares, suggesting the position is held in a non-discretionary capacity.

• · Clear Street Derivatives LLC has sole voting power over 0 shares and sole dispositive power over 0 shares, indicating the shares are held in a non-discretionary or custodial capacity.
• · The filing is an amendment (SCHEDULE 13G/A) to a prior Schedule 13G filing.
• · The filing was made pursuant to Rule 13d-1(d), which is used by institutional investors who acquired shares in the ordinary course of business and not with the purpose of changing or influencing control.

18-08-2026

First City Investment Group, LLC filed an amended Schedule 13G with the SEC, disclosing beneficial ownership of 37,153 shares of Generation Income Properties, Inc. common stock, representing approximately 2.0% of the 1,861,303 shares outstanding as of August 14, 2026. The filing was made under Rule 13d-1(c) and includes a certification that the shares were not acquired to change or influence control of the issuer. This is a routine passive ownership update and indicates a very small stake with no apparent intent to exert influence.

• · The filing is an amendment (Schedule 13G/A) filed on August 18, 2026, with an event date of August 17, 2026.
• · First City Investment Group, LLC is a Delaware limited liability company with its principal business address in Encino, California.
• · The filing certifies that the securities were not acquired with the purpose or effect of changing or influencing control of the issuer.

18-08-2026

BJI Financial Group filed an amended Schedule 13G with the SEC on August 18, 2026, disclosing beneficial ownership of 457,282 common shares of C1 Fund Inc. (CFND), representing 6.85% of the outstanding shares. The filing indicates the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.